Please use this identifier to cite or link to this item: https://repositorio.unifesp.br/handle/11600/45721
Title: COMPARISON OF 3 DIFFERENT SCHEDULES OF VACCINATION AGAINST HEPATITIS-B IN HEALTH-CARE WORKERS
Authors: Oliveira, Patricia MC [UNIFESP]
Silva, A. Eduardo [UNIFESP]
Kemp, Vitorio L. [UNIFESP]
Juliano, Yara [UNIFESP]
Ferraz, M. Lucia [UNIFESP]
Universidade Federal de São Paulo (UNIFESP)
Keywords: HEPATITIS B
HEPATITIS B VACCINE
IMMUNIZATION
Issue Date: 1-Jun-1995
Publisher: Butterworth-heinemann Ltd
Citation: Vaccine. Oxford: Butterworth-heinemann Ltd, v. 13, n. 9, p. 791-794, 1995.
Abstract: Health cave workers (HCW) are a group at risk for hepatitis B virus (HBV) infection; as a result, vaccination is recommended. However, elevated cost of the vaccination schedule is one of the limiting factors to this approach. Our aim in this study was to evaluate alternative schedules for vaccination against hepatitis B, in order to obtain safe immunization with reduced costs. We studied 300 HCW, randomized to be submitted to one of three vaccination schedules against hepatitis B: Group A-three doses of 20 mu g i. m. (n=103); Group B-first dose i.d. (2 mu g), second and third doses im. (20 mu g) (n=97), Group C-first and second doses i.d. (2 mu g), third dose i.m. (20 mu g) (n=100). All individuals received recombinant vaccine at 0, 1 and 6 months. After the first dose, there was no difference among the three schedules, either in terms of anamnestic response or in seroconversion rate. After the second dose, there was statistical difference among the three schedules (A>B>C), in terms of seroconversion rates. After the third dose, seroconversion rates were 92.2% in Group A and 92.8% in group B; geometric mean titers (GMT) in Group B (789.6 UI l(-1) were similar to group A (1248.0 UI l(-1)). Group C presented a seroconversion rate of 78% and a GMT of 323.0 UI l(-1), both statistically inferior to other schedules. We concluded that the schedule applied in Group B had similar results when compared to schedule A, with estimated savings of 30% in vaccine costs. However, a long-term follow-up is necessary to evaluate its cost-effectiveness.
URI: http://repositorio.unifesp.br/11600/45721
ISSN: 0264-410X
Other Identifiers: http://dx.doi.org/10.1016/0264-410X(94)00064-T
Appears in Collections:Artigo

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.